Interferon (IFN)-l1, -2 and -3 (also designated as interleukin (IL)-29, IL-28a and IL-28b) represent a new subfamily within the class II cytokine family. They show type I IFN-like antiviral and cytostatic activities in affected cells forming the basis for IFN-l1 therapy currently under development for hepatitis C infection. However, many aspects of IFN-ls are still unknown. This study aimed at identifying the target cells of IFN-ls within the immune system and the skin. Among skin cell populations, keratinocytes and melanocytes, but not fibroblasts, endothelial cells or subcutaneous adipocytes turned out to be targets. In contrast to these target cells, blood immune cell populations did not clearly respond to even high concentrations of these cytokines, despite an IFN-l receptor expression. Interestingly, immune cells expressed high levels of a short IFN-l receptor splice variant (sIFN-lR1/sIL-28R1). Its characterization revealed a secreted, glycosylated protein that binds IFN-l1 with a moderate affinity (K D 73 nM) and was able to inhibit IFN-l1 effects. Our study suggests that IFN-l therapy should be suited for patients with verrucae, melanomas and non-melanoma skin cancers, apart from patients with viral hepatitis, and would not be accompanied by immune-mediated complications known from type I IFN application.
Introduction
Human interferon (IFN)-l1, -2 -and -3 (also designated as interleukin (IL)-29, IL-28a and IL-28b, or type III IFNs) are highly related cytokines that were independently discovered in 2003 by two research groups. 1, 2 The aminoacid sequences of IFN-l2 and IFN-l3 are virtually identical (94%), those of IFN-l2 and IFN-l1 share 66%. These mediators are part of a larger family of structurally related cytokines called the class II cytokine family, which also contains the IL-10-related cytokines (IL-10, IL-19, IL-20, IL-22, IL-24 and IL-26), type I IFNs and IFN-g. [3] [4] [5] Within the class II cytokine family, IFN-ls form a theoretical bridge between IL-10-related cytokines on the one side and type I IFNs on the other, because they are closer to the first in terms of the structure of their encoding genes, their spatial protein structure and their receptor usage, but their activities mimic many functional aspects of type I IFNs. 1, 2, [6] [7] [8] All three cytokines share the same receptor complex that consists of IFN-lR1 (also designated as IL-28R1) and IL-10R2, 1,2 with IL-10R2 also being part of the receptor complexes for IL-10, IL-22 and IL-26. 4, 5 As for the type I IFN system, engagement of the IFN-l receptor complex leads to the activation of signal transducers and activators of transcription (STAT)1 and STAT2, which, together with IFN regulatory factor-9, form a transcriptional complex called IFN-stimulated gene factor-3. 1, 7, 9 This factor induces the so-called IFN-stimulated genes (ISGs). Moreover, an engagement of the IFN-l receptor activates STAT3 and STAT5, 1 which also represents a main feature of signal transduction induced by IL-10-related cytokines. 5 Up to now, research has mainly focused on the role of IFN-ls in viral infections, which is also an important feature of the type I IFN action. IFN-ls seem to be produced by any nucleated cell type after viral infection or viral infection-mimicking agents such as polyinosinicpolycytidylic acid (poly(I:C)). 10 A particularly high expression was observed in infected plasmacytoid dendritic cells (DCs), 11 the distribution of which may influence the quantity of IFN-l production in a respective tissue. Moreover, IFN-ls exert direct antiviral activities by inducing antiviral proteins, 1, 2, 6, [12] [13] [14] and upregulating the cellular major histocompatibility complex class I (MHC I). 1, 15, 16 Apart from their role during viral infection, IFN-ls, similar to type I IFNs, may be important in fighting against bacterial infections. In fact, these cytokines are produced by monocytic cells after activation with bacterial lipopolysaccharides (LPS), and especially during LPS-induced maturation of monocytic DCs, 11, 17 and they enhance the expression of bacterial component sensing Toll-like receptors. 17 Finally, an antiproliferative effect on some tumor cell lines was demonstrated for IFN-ls, 7, 12, 18, 19 an effect that is also shared by type I IFNs.
The overlapping activities exerted by type I and type III IFNs would suggest a redundancy between both IFN systems. However, there is growing evidence that in contrast to the lacking cell specificity of type I IFNs, IFNls do not target every type of cell. 15, [19] [20] [21] [22] For instance, whereas IFN-ls exerted clear effects on different epithelial cell populations and, at least in humans, on hepatocytes, no influence could be detected on endothelial cells of the brain and kidney. 2, 6, 12, 17, 22 A more selective target cell range would be of great importance for the possible therapeutic applications of IFN-ls. Although it would reduce the number of potential medical indications, the limitation of side effects would represent a big advantage over type I IFNs. To better understand which cells are responsive to the action of IFN-ls, this work aimed at identifying target cells of type III IFNs.
Results
Expression of IFN-lR1 mRNA in human tissues and in cell populations of the immune system and the skin The IFN-ls are newly discovered cytokines, the target cells of which have not been completely uncovered. We therefore aimed at further characterizing the IFN-l targets in the human system. We first analyzed 28 human tissues for the expression of the IFN-l receptor. As IL-10R2, one of the two components of this receptor complex, which is also shared by other cytokines, was already known to be ubiquitously expressed, 23 we focused on the expression of the IFN-lR1 receptor component. As demonstrated by real-time PCR on reverse-transcribed cDNA (qPCR), IFN-lR1 could be detected in all analyzed tissues, although, unlike IL-10R2, the expression level greatly varied among tissues (Figure 1a) . Interestingly, the liver and lungs showed the highest levels, and the main organs of the immune system (spleen, thymus, peripheral blood mononuclear cells (PBMCs)), as well as the skin, were also among those organs expressing above-average IFN-lR1 levels. In contrast, the brain showed very low levels ( Figure 1a ), which is in line with previous results on limited brain cell/tissue receptor expression and IFN-l sensitivity. 2, 19 Because organs are constructed of different cell types, we further analyzed the expression of IFN-lR1 in cell populations of two organs that we are especially interested in, the immune system and the skin. Figure 1b , B cells and keratinocytes showed a very high IFN-lR1 expression, followed by hepatocytes/HepG2, T cells and melanocytes. In contrast, NK cells and monocytes expressed rather moderate levels of IFN-lR1, and minimal or even no expression at all was found in microvascular endothelial cells, fibroblasts and adipocytes.
Sensitivity of selected cell populations toward type III IFNs
The different cellular IFN-lR1 expression levels suggested different sensitivities of the analyzed cell populations toward IFN-ls. To prove this assumption, we investigated signal transduction pathways in selected cell populations. To begin with, total PBMCs, keratinocytes, melanocytes, dermal endothelial cells and HepG2 cells were stimulated with IFN-l2 and IFN-l1 for 0 (controls), 10 and 20 min, and were analyzed for cellular phospho-STAT1, -STAT3 and -STAT5 content by western blot analysis. As shown in Figure 2a , keratinocytes, melanocytes and HepG2 cells responded to these cytokines by mainly activating STAT1. With the exception of melanocytes, IFN-l1 was much more potent than IFN-l2, and signals increased with time. In contrast, stimulation of PBMCs with IFN-l2 and IFN-l1 resulted in only minimal, if any, STAT1 activation (and no STAT3 or STAT5 activation), whereas IFN-g and IFN-b1 strongly induced STAT1 and STAT3 activation in these cells. In line with the minimal IFN-lR1 expression, neither IFNl2 nor IFN-l1 induced STAT activation in endothelial cells (data not shown). We then investigated STAT activation by IFN-ls separately in monocytes, B, T and NK cells using intracellular staining of phospho-STAT1 and -STAT3 and flow cytometry. In these experiments, we increased the concentration of IFN-ls to 100 ng ml À1 . We found that IFN-l2 and IFN-l1 did not activate STAT1 or STAT3 at all in monocytes, T or NK cells. In B cells, a reproducible, although minimal, activation of STAT1 and STAT3 was seen (Figure 2b ). In further experiments, an increase in IFN-l1 concentration to even 1 mg ml À1 could not induce STAT1 or STAT3 activation in monocytes or T cells, as shown by the dose-response analysis presented in Figure 2c .
To include a second parameter indicating a possible sensitivity of cells toward IFN-ls, we analyzed the IFNl-dependent increase of MHC I surface expression. In line with the results obtained from the signal transduction analysis, IFN-l2 and IFN-l1 showed a dosedependent upregulation of MHC I surface expression on HepG2 cells, keratinocytes and melanocytes, whereas 10 or 100 ng ml À1 of these cytokines did not provoke this effect in the blood immune cell populations ( Figure 3a) .
As immune cells could be responsive toward IFN-ls only after previous stimulation, we then prestimulated PBMCs for 24 h with the following cell-specific stimuli: LPS for the stimulation of monocytes, fixed Staphylococcus aureus cells for B cells, immobilized anti-CD3/anti-CD28 monoclonal antibodies (mAbs) for the stimulation of T cells and IL-2/IL-12 for the preferential stimulation of NK cells. Additional PBMCs were prestimulated with poly(I:C), a TLR3 ligand. After extensive washing, cells were stimulated with IFN-l2, IFN-l1 and IFN-b1 for a further 24 h and assessed for MHC I expression. However, none of the pretreatment protocols could induce a convincing responsiveness of the different PBMC subpopulations to IFN-ls. Figure 3c shows respective data obtained with monocytes. Interestingly, the specific prestimulations actually led to a decrease in IFN-lR1 expression in the different PBMC subpopulations (Figure 3b ).
Protein expression of IFN-lR1 and IL-10R2 in blood immune cells and keratinocytes The lack or minimal sensitivity of tested immune cells to IFN-ls raised the question of the cause of this phenomenon. A possible explanation is a lacking translation of IFN-lR1 mRNA into protein in these cells. We therefore analyzed the IFN-lR1 protein levels in PBMCs from different donors compared with keratinocytes and HepG2 cells using the western blot technique. As shown in Figure 4 , in all cell populations including PBMCs, a clear main band of a size of approximately 70 kDa and, with the exception of keratinocytes, some ancillary bands probably corresponding to differently glycosylated forms of membrane-associated IFN-lR1 could be detected. Whereas the main band was most pronounced in HepG2, its intensity was comparable or even more pronounced in PBMCs compared with keratinocytes. As expected, all analyzed cells also expressed IL-10R2 (55-60 kDa; Figure 4 ). These results exclude that immune cells fail to express IFN-lR1 protein.
Characterization of a short IFN-lR1 variant as a potential mediator of cellular insensitivity toward IFN-ls Another cause of the minimal sensitivity of tested immune cells toward IFN-ls could be the possible expression of an inhibitory IFN-lR1 variant. In fact, Sheppard et al. 2 and Dumoutier et al. 24 have described the existence of different IFN-lR1 mRNA splice variants. One of these variants lacks the sequence that is currently designated by the NCBI as the first part of exon VII, resulting in a 29 amino-acid deletion within the intracellular domain. 2 Another splice variant lacks the sequence that corresponds to the transmembrane domain-containing exon VI, resulting in a frameshift with an alternative, premature stop codon. 24 So far, neither the existence as proteins nor the cellular sources, expression levels or the function of the alternative IFNlR1 forms is known. We therefore established a PCR assay to simultaneously amplify all these IFN-lR1 forms (spanning exons V-VII), and analyzed cDNAs from PBMCs, keratinocytes and HepG2 cells in this regard. As demonstrated in Figure 5a , the PCR products obtained with all cells each represented a long and a short IFNlR1 form. Interestingly, keratinocytes and HepG2 cells expressed predominantly the longer form, whereas PBMCs expressed considerably less of the long IFNlR1 form but more of the shorter form. By sequencing, we identified the long form as the complete IFN-lR1 cDNA fragment, representing the membrane-associated variant (memIFN-lR1). The shorter form (sIFN-lR1) turned out to lack the exon VI sequence and, therefore, corresponds to the mRNA splice variant predicted by Dumoutier et al. 24 The deduced protein sequence (244 amino acids) lacks the transmembrane and intracellular domain encoding parts and corresponds to the extracellular domain of memIFN-lR1 with the exception of the five C-terminal amino acids that are replaced by 21 amino acids generated by a frame shift (Figures 5b and c) . Therefore, sIFN-lR1 may represent a secreted, singlechain receptor that should have IFN-l-binding sites identical to memIFN-lR1. The identity of these IFN-lR1 forms was additionally confirmed at the mRNA level by PCR assays covering longer fragments of the IFN-lR1 sequence (exons II-VII) and subsequent sequencing (data not shown). No further variant was found in any of these reactions.
In the next step, we quantified the expression of both IFN-lR1 forms using specific qPCR assays and calculated their expression ratios in separated monocytes, B, T and NK cells, as well as in keratinocytes, hepatocytes and HepG2 cells. Consistent with our results from the conventional PCR, the expression ratio between the long For PBMCs, stimulation with 10 ng ml À1 IFN-g and 500 U ml À1 IFN-b1 was additionally included as a positive control. Tyrosine phosphorylation of STAT molecules was assessed by western blot analysis. One representative of two experiments of each cell type is shown. (b) PBMCs were stimulated or not (control) for 20 min with 100 ng ml À1 IFN-l2, 100 ng ml À1 IFN-l1, 10 ng ml À1 IFN-g and 500 U ml À1 IFN-b1. Levels of tyrosine phosphorylation of STAT1 and STAT3 in different PBMC subpopulations were assessed by respective intracellular staining and flow cytometry. Data from five independent experiments are given as percentage of untreated controls calculated on the basis of measured mean fluorescence intensities (MFIs; mean±s.e.m.). Significance of differences to respective untreated controls was analyzed using the Wilcoxon matched-pairs signed-rank test (*Po0.05). (c) PBMCs were stimulated for 20 min with 0, 10, 100 and 1000 ng ml À1 IFN-l1 or IFN-b1. Monocyte and T-cell tyrosine phosphorylation of STAT1 and STAT3 was assessed as in (b). Data from three independent experiments are given as MFIs calculated as differences between treated and untreated cells (mean ± s.e.m.).
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and the short form was cell specific (Figure 5d ), whereas keratinocytes, hepatocytes and HepG2 cells showed mean expression ratios of higher than seven (7.3, 10.4 and 15.2, respectively); the ratio in the different immune cell populations was as low as 1.6-3.6. This finding provoked the hypothesis that for the sensitivity of cells to IFN-ls not only the expression level of the signaling competent IFN-lR1 receptor but also the memIFN-lR1/sIFN-lR1 expression ratio may be of importance.
To investigate whether this hypothesis is true, in the next part of our study, we biochemically and functionally characterized sIFN-lR1. For that purpose, this splice variant fused to a His 6 and a V5 tag was transiently overexpressed in HepG2 cells by transfection. As a control, a construct containing His 6 -and V5-tagged IL-22 binding protein (IL-22BP), the secreted single-chain receptor for IL-22, was transfected in parallel. Western blot analysis using anti-V5 tag polyclonal antibodies À1 IFN-g and 500 U ml À1 IFN-b1 was additionally included as positive controls. Cellular MHC I expression was assessed by respective cell-surface staining and flow cytometry. Data from five independent experiments are given as percentage of untreated control calculated on the basis of mean fluorescence intensities (MFIs; mean ± s.e.m.). Significance of differences to respective untreated controls was investigated by use of the Wilcoxon matched-pairs signed-rank test (*Po0.05). (b) PBMCs were stimulated with 100 ng ml À1 bacterial LPS (stimulation of monocytes), with heat-killed, formalin-fixed S. aureus cells (stimulation of B cells), IL-2/IL-12 (stimulation of NK cells) and anti-CD3 mAb/anti-CD28 mAb (stimulation of T cells) for 6 h. IFN-lR1 expression was analyzed by qPCR and representative data from one out of two experiments are given as normalized to hypoxanthine phosphoribosyl-transferase 1 (HPRT) expression. (c) PBMCs were prestimulated with bacterial LPS, poly(I:C) or were left without prestimulation for 24 h. After washing, prestimulated samples were restimulated or not (control) with 100 ng ml À1 IFN-l2, 100 ng ml À1 IFN-l1 and 500 U ml À1 IFN-b1 for 24 h. Monocyte MHC I expression was assessed by respective cell-surface staining and flow cytometry. Data from three independent experiments are given as percentage of untreated control without prestimulation, calculated on the basis of MFIs (mean±s.e.m.). (pAbs) showed that the sIFN-lR1 variant, similar to IL-22BP, could be detected in both the cell lysate and the cell culture supernatant of transfected HepG2 cells (Figure 6a ). These data show that sIFN-lR1 is in fact a soluble receptor as it is at least partly secreted. The occurrence of several bands in these analyses additionally suggested that sIFN-lR1 is a glycosylated protein. Its glycosylation pattern in the cell lysate, similar to that of IL-22BP, differed from that found in the cell culture supernatant, suggesting that these proteins are not secreted until full glycosylation is achieved. Enzymatic N-deglycosylation led to clear bands of about 32 kDa for both the IFN-lR1 variant and IL-22BP, proving respective glycosylation ( Figure 6b ). We then investigated whether the recombinant-produced sIFN-lR1 was able to bind IFN-l1. By means of the surface plasmon resonance technique, sIFN-lR1 and, as a control, IL-22BP were run at different concentrations over a sensor chip surface coated with IFN-l1 in the first flow cell and IL-22 in the second flow cell. The increase in resonance units (RU) was recorded as a measure of the density of receptor molecules bound to the chip in a defined period of time. As shown in Figure 6c , sIFN-lR1 dose dependently bound to immobilized IFN-l1, but not to immobilized IL-22. It is noteworthy that binding to IFN-l1 seemed to be less pronounced than that of IL-22BP to IL-22.
Soluble receptors may act as negative regulators of cytokine actions by preventing their binding to the membrane-bound receptor. Most of such soluble receptors, including IFNaRba, are splice variants corresponding to the extracellular moieties of respective membraneassociated receptor variants. 25 To get further insight into the biological role of sIFN-lR1, we aimed at investigating (1) its affinity to IFN-l1 and (2) its ability to inhibit the cellular IFN-l1 action. As the answers to these questions require a high amount of recombinant sIFN-lR1, for these experiments, we used a commercially available Fccoupled molecule construct (sIFN-lR1-Fc). The affinity between sIFN-lR1-Fc (immobilized) and IFN-l1 was measured by means of the surface plasmon resonance technique. Calculated on the basis of their interaction on binding equilibrium, the K D value was approximately 73 nM (Figure 7a) .
To investigate whether sIFN-lR1 would inhibit the IFN-l1 action on cells, we used HepG2 cells. These cells were stimulated with 10 ng ml À1 IFN-l1 or 500 U ml À1 IFN-b1, which had been preincubated with 1 and 10 mg ml À1 of sIFN-lR1-Fc. The cytokine-induced MHC I increase was assessed by flow cytometric analysis as before. As demonstrated in Figure 7b , sIFN-lR1-Fc dose dependently prevented the IFN-l1-induced upregulation of MHC I. The prevention obtained with 10 mg ml À1 was approximately 70%. No influence of sIFN-lR1-Fc on the IFN-b1-induced MHC I upregulation was observed (Figure 7b ).
These data suggest that sIFN-lR1, at least at high local concentration, inhibits IFN-l1 action and may be a candidate responsible for the observed lack/minimal response of investigated immune cells to IFN-ls.
Discussion
Type I IFNs are mediators that are very important for first-line antiviral and antitumor effector mechanisms, and they also show immunomodulatory activities. Their importance is especially reflected by their widespread clinical use in viral infections such as hepatitis C and B viruses, in cancers such as melanoma and hairy cell leukemia and in multiple sclerosis. [26] [27] [28] [29] However, a major limitation of type I IFN therapy is the frequent occurrence of side effects: in particular influenza-like symptoms, fatigue, suppression of bone marrow, induction or exacerbation of autoimmune disorders, neurotoxic reactions and emotional depression. Moreover, people may become resistant to type I IFNs. 30 Therefore, the therapeutic potential of the only recently discovered type III IFNs IFN-l1, 2 and 3, which seem to mimic the direct antiviral and antitumor activities of type I IFNs, seems to be very promising. The antiviral effects of IFNls were so convincing that an application of IFN-l1 to Aiming to identify target cell populations especially within the human immune system and the skin for these mediators, in this study we observed that keratinocytes and melanocytes expressed significant levels of IFN-lR1 and clearly responded to IFN-l stimulation. Although this sensitivity of keratinocytes has already been described by our group, 17 our study now revealed for the first time that IFN-ls influence human melanocytes. In line with previously published data, 19 ,31 IFN-l1 was much more potent than IFN-l2 in keratinocytes, as was the case in hepatocytes. Interestingly, however, IFN-l1 and IFN-l2 were similarly potent in melanocytes. In contrast to keratinocytes and melanocytes, IFN-lR1 expression in dermal endothelial cells and fibroblasts and in subdermal adipocytes was very low or even absent, and endothelial cells did not respond to IFN-ls (fibroblasts and adipocytes were not tested).
Interestingly, with the exception of a very weak response of B cells, human blood immune cells did not respond to type III IFNs. In these cells, cytokines neither activated typical signal transduction elements such as STAT 1 or 3 nor caused MHC class I upregulation even at very high doses. In the literature, the responsiveness of immune cells was very controversially discussed: for example, Ank et al. 20 demonstrated that no relevant ISG induction could be achieved by these cytokines in mouse macrophages or myeloid DCs. Moreover, Lasfar et al. 15 demonstrated the lack of STAT activation by type III IFNs in mouse splenocytes and bone-marrow-derived macrophages. Sommereyns et al., 22 by using plasmid electrotransfer-mediated expression of IFN-l3 and measuring the IFN-l in vivo response by monitoring organ ISG expression, found no clear response in the spleen. In contrast to these investigations, some studies did propose direct effects of IFN-ls on monocytes, 32, 33 DCs 34 and T cells. [35] [36] [37] [38] [39] [40] We currently cannot explain the discrepancy in these observations in terms of whether IFN-ls influence, for example, monocytes or T cells. As we demonstrated, it seems that the preactivation with cell-specific stimuli or virus-mimicking agents could not confer any clear responsiveness to these cytokines on peripheral immune cells. However, these data do not totally exclude any sensitivity to IFN-ls, for example, occurring in small subpopulations or achieved on special activation/differentiation states of immune cells.
Interestingly, the lack of or minimal immune cell responsiveness to IFN-ls observed in our study was not simply because of the lack or minimal expression of the respective receptor in the immune cells. In fact, of all cell populations tested in our study, B cells even showed the highest IFN-lR1 mRNA expression and the expression in T cells was at least comparable with those of melanocytes and hepatocytes/HepG2 cells. We also clearly detected IFN-lR1 protein in PBMCs. A similarly lacking response of cells that express significant levels of IFN-lR1 mRNA was previously recognized by Meager et al. 19 on analysis of a range of human tumor cell lines.
Many different mechanisms could be responsible for the fact that, despite a clear receptor expression, immune cells do not respond to IFN-ls. These mechanisms include the possible lack of surface expression of IFN-lR1 or IL-10R2; the existence of alternative receptor glycosylation patterns determining the functionality of the receptor; the existence of intracellular factors that negatively regulate IFN-lR1 signal transduction and the presence of a blocking decoy or soluble receptor for IFN-ls. We, along with others, demonstrated that immune cells clearly express IL-10R2 mRNA 23, 41, 42 and protein (Figure 4) , and that these cells react to IL-10, 41 which proves the functionality of IL-10R2 on the cell surface.
In our study, we focused on the investigation of the possible expression of nonfunctional or blocking IFN-lR1 variants. No expression of mRNA encoding a cell-associated IFN-lR1 variant with a truncated (23) 100 (46) 0.6 -5 (45) (46) (47) (48) (49) > 0.4 (45, 46, 48, 49) + + + + + + 10 µg/ml À1 IFN-l1 and 500 U ml À1 IFN-b1, which had been preincubated for 2 h with 0, 1 and 10 mg ml À1 sIFNlR1-Fc. Major histocompatibility complex class I (MHC I) cellsurface expression was measured by flow cytometry. Data from six independent experiments are given as a percentage of the respective group without sIFN-lR1-Fc, calculated on the basis of mean fluorescence intensities (MFIs; mean ± s.e.m.). Significance of differences to the respective untreated control was analyzed using the Wilcoxon matched-pairs signed-rank test (*Po0.05).
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intracellular domain that could function as a decoy receptor was found by us in any of the cells tested. However, we actually found an increased relative expression of a very short variant in immune cells. The recombinant expression of the respective protein revealed a glycosylated, secreted molecule. We proceeded on the assumption that the affinity of sIFN-lR1 to IFN-l1 may be very similar to that of sIFN-lR1-Fc and that of memIFN-lR1, because, with the exception of the five C-terminal amino acids, the sequence of sIFN-lR1 comprises that encoding the extracellular domain of memIFN-lR1. We demonstrated that this protein was able to bind IFN-l1 with a moderate affinity. In fact, the K D value of 73 nM indicated an approximately 100 times lower binding than that for the interaction of IL-22 with its potently inhibiting soluble receptor IL-22BP, as previously determined by our laboratory. 43 Moreover, the sIFN-lR1-Fc-IFN-l1 binding had a similar (IFN-a1) or lower (IFN-a2, IFN-b) affinity compared with the binding of the extracellular domain of the R1-type IFN receptor subunit IFN-aRB to the respective type I IFN [44] [45] [46] [47] [48] ( Figure 7a) . Our yet preliminary data also indicated that the affinity of sIFN-lR1-Fc to IFN-l1 was similar to the affinity to IFN-l2.
Importantly, sIFN-lR1-Fc was able to inhibit cellular IFN-l responses effectively, suggesting that it may exert an effect, at least under some circumstances, as a negative regulator of the action of these cytokines. Therefore, although a threshold memIFN-lR1 level seems to be the prerequisite for cellular IFN-l responses, 9 the ratio of the local expressions of memIFN-lR1 and sIFN-lR1 should also be of importance. The elevated expression of an sIFN-lR1 splice variant may therefore represent one, but not necessarily the exclusive mechanism of the minimal IFN-l sensitivity of immune cells.
However, there remain some questions to be answered in further studies. For instance, are there other mechanisms that contribute to the minimal IFN-l sensitivity of immune cells? Are the sIFN-lR1 levels secreted in vivo by immune cells high enough to also influence the responsiveness of neighboring cells? Are there mechanisms to concentrate sIFN-lR1 around the cells that produce it?
In summary, our study supports that IFN-ls do not influence every type of cell and that memIFN-lR1 expression is not sufficient to ensure cellular sensitivity toward these cytokines. In particular, the data show that immune cells are not major targets of IFN-ls, and that sIFN-lR1 may be a factor contributing to the cellular insensitivity toward these cytokines. In contrast to immune cells, a couple of skin cell populations, namely, keratinocytes and melanocytes, are major targets of these cytokines. We conclude that type III IFNs may be promising candidates for therapeutic application not only in viral hepatitis but also in epidermal viral infections such as human papillomavirus-associated verrucae, in epidermal carcinoma such as basal cell and squamous cell carcinoma, as well as in melanoma. Because cells of the immune system and of the central nervous system are not major targets of type III IFNs, a therapeutic application of these cytokines should not be accompanied by flulike symptoms, induction or exacerbation of autoimmune disorders or neurotoxic reactions. Further studies are needed to prove the efficacy of type III IFNs in treating these skin disorders.
Materials and methods

Cell culture
Peripheral blood mononuclear cells were separated from the blood of healthy donors by Ficoll-Paque densitygradient centrifugation (Pharmacia, Freiburg, Germany). For some experiments, monocytes, B-, T-and NK cells were isolated from PBMCs using the MACS system (Miltenyi Biotec, Bergisch-Gladbach, Germany), and either positive (monocytes, B cells, T cells used without culture in Figures 1b and 5d) or negative (NK cells used without culture in Figures 1b and 5d , and all subpopulations used for stimulation experiments in Figure 3b ) selection was used. Cells were either prepared directly after separation for IFN-lR1 mRNA expression analysis or, for stimulation experiments, were cultured under low endotoxin conditions as described previously. 49 Primary human hepatocytes were obtained from Lonza (Verviers, Belgium) and cultured with HGM medium (Lonza) on thin-layer Biocoat Matrigel (BD Biosciences, Heidelberg, Germany) according to the manufacturer's instructions. HepG2 cells were purchased from the European Collection of Cell Cultures (Salisbury, UK) and maintained according to the supplier's instructions. Primary human epidermal keratinocytes and dermal fibroblasts were obtained from Lonza and cultured in KGM and FGM-2 medium, respectively, from the same supplier. Adipocytes were generated from primary human subcutaneous preadipocytes (Lonza) by culturing them for 10 days with PGM-2 differentiation medium (Lonza). Primary human melanocytes were purchased from Invitrogen (Karlsruhe, Germany) and cultured in the respective medium (Invitrogen) according to the supplier's instructions. Primary human dermal microvascular endothelial cells were purchased from Invitrogen and ProVitro (Berlin, Germany) and cultured according to the suppliers' instructions. All these cells were used for direct analysis or stimulation experiments after a 24-48 h preculture period. For western blot analysis of STAT phosphorylation, PBMCs, after a preculture period of 1.5 h, as well as keratinocytes, melanocytes, endothelial cells and HepG2 cells, were each stimulated with 40 ng ml À1 IFN-l2 and 40 ng ml À1 IFN-l1 for 10 and 20 min, or were left unstimulated (controls); for PBMCs, additional stimulation with 10 ng ml À1 IFN-g or with 500 U ml À1 IFN-b1 was performed. For flow cytometric analysis of STAT phosphorylation in PBMC subpopulations, we stimulated PBMCs, after being precultured for 1.5 h, if not indicated otherwise (as in Figure 2c) , with 100 ng ml À1 IFN-l1, 100 ng ml À1 IFN-l2, 10 ng ml À1 IFN-g or 500 U ml À1 IFN-b1 for 20 min, or were left unstimulated (controls). For the flow cytometric quantification of MHC I expression, PBMCs, keratinocytes, melanocytes and HepG2 cells were stimulated or not (control) each with 10 and 100 ng ml À1 of IFN-l2 and IFN-l1 for 24 h; PBMCs were additionally stimulated with 10 ng ml À1 IFN-g and 500 U ml À1 IFN-b1. In a separate experimental setting, PBMCs, before measuring their MHC I response to IFN-l2, IFN-l1 and IFN-b1 with respect to different subpopulations, were prestimulated with 100 ng ml À1 LPS from Escherichia coli 0127:B8 (Sigma-Aldrich Chemie, Deisenhofen, Germany) (stimulation of monocytes); with 0.001% (w/v) heat-killed, formalin-fixed S. aureus cells (PANSORBIN; CalbiochemNovabiochem, Bad Soden, Germany) (stimulation of B ) (stimulation of T cells); 10 mg ml À1 poly(I:C) (Sigma-Aldrich) as well as with medium, for 24 h, and were then extensively washed. In addition, isolated monocytes, B, T and NK cells were stimulated with LPS, S. aureus, IL-2/IL-12 and anti-CD3/anti-CD28 mAb as described above for 6 h, and were lysed for IFN-lR1 mRNA analysis.
For recombinant expression of sIFN-lR1 and IL-22BP in HepG2 cells, we performed cellular transfection with corresponding plasmids (see below) using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions after subsequent culturing in Eagle's Minimal Essential Medium (EMEM; Sigma-Aldrich) supplemented with 10% fetal bovine serum and 2 mM glutamine (both from Biochrom, Berlin, Germany), gentamycine sulfate and amphotericin B (both from Lonza) for 72 h. Afterward, cell culture supernatants were collected and cells were lysed for protein analyses.
To investigate the influence of sIFN-lR1 on IFN-l1-induced MHC I expression, we stimulated HepG2 cells for 24 h with 10 ng ml À1 IFN-l1, 500 U ml À1 IFN-b1 or a respective volume of culture medium, each of which had been preincubated with 1 or 10 mg ml À1 of sIFN-lR1-Fc (R&D Systems) for 2 h. The sIFN-lR1-Fc construct contains two bound copies of the complete extracellular domain of IFN-lR1 linked by a peptide of six amino acids (IEGRMD) to a fragment (P 100 to L 330 ) of human immunoglobulin (Ig)G1. All cytokines and antibodies mentioned above were purchased from R&D Systems. All experiments in a given test series on immune cells and keratinocytes were conducted with cells from different donors.
Plasmid construction and transfection
Plasmids encoding either sIFN-lR1 (NM_173065) or IL-22BP (NM_181309) (open reading frame (ORF) 1) under the control of the human EF-1a promoter, which in addition contain the sequence of a His 6 and V5 protein tag (ORF 2), were purchased from RZPD (Berlin, Germany). To fuse the two ORFs, the stop codon of the first ORF was deleted by the use of site-directed mutagenesis as follows-first, PCR was performed using the following primers: BstBI (sIFN-lR1) or BstXI and BstBI (IL-22BP), and vector backbone fragments were ligated to digested PCR products using T4 DNA-Ligase (New England Biolabs, Frankfurt am Main, Germany). Final plasmids were propagated in E. coli (One Shot MAX Efficiency DH5a-T1; Invitrogen) and reisolated (EndoFree Plasmid Maxi Kit; Qiagen, Hilden, Germany). Successful mutagenesis was approved by sequencing by means of the ABI Prism BigDye Terminator cycle sequencing kit and the ABI 310 capillary electrophoresis genetic analyzer (both from Applied Biosystems, Darmstadt, Germany). Restriction endonucleases were purchased from New England Biolabs, except AaRI, which was purchased from Fermentas (St Leon-Rot, Germany).
Purification of recombinant sIFN-lR1 and IL-22BP For overexpression of recombinant sIFN-lR1 and IL-22BP and subsequent purification, we adapted HepG2 cells to serum-free EMEM medium (Sigma-Aldrich), supplemented with SynQ (Cell Culture Services, Hamburg, Germany) and transfected afterward as described above, whereby the medium was changed 6 h after transfection to a new medium supplemented with gentamycine, amphotericin B (Lonza) and protease inhibitors (P1860; Sigma-Aldrich). Culture supernatants were collected 4 days after transfection and dialyzed against a specific native binding buffer (25 mM TRIS-HCl (pH 8.0), 500 mM NaCl, 2 mM Imidazole; Amocol, Teltow, Germany). Overexpressed sIFN-lR1 and IL-22BP were purified by His-tag using cobalt affinity chromatography columns (Amocol) under native conditions according to the manufacturer's instructions, whereby all buffers used were supplemented with protease inhibitors (Complete EDTA-free; Roche Diagnostics, Mannheim, Germany). Concentrations of protein solutions were obtained by repeated ultracentrifugation using Amicon Ultra-4 devices (Millipore, Schwalbach/Ts, Germany), whereby the buffer was changed to phosphate-buffered saline. The quality of purified protein was checked by western blot analysis as described below and protein concentration was assessed using BCA protein quantification assay (Perbio, Bonn, Germany).
Western blot analysis
For these analyses, cell lysis, measurement of protein concentration, protein electrophoresis and western blotting were performed as described previously. 50 For signal transduction analyses, blotted samples were incubated with pAbs against phospho-STAT1 (Tyr701), phospho-STAT3 (Tyr705), phospho-STAT5 (Tyr694) or total STAT3 (all from Cell Signaling Technology, Beverly, MA, USA), and, as secondary antibodies, with peroxidase-conjugated AffiniPure goat anti-rabbit IgG (H and L; Dianova, Hamburg, Germany), followed by enhanced chemiluminescence (ECL) detection (Amersham Pharmacia Biotech, Freiburg, Germany). For the detection of IFN-l receptor components, we incubated blots with anti-IFNlR1 pAbs (50 ng ml
À1
; Sigma-Aldrich), anti-IL-10R2 pAbs (600 ng ml À1 ; R&D Systems) and anti-GAPDH mAb (200 ng ml
; clone 6C5; Millipore), followed by peroxidase-conjugated AffiniPure goat anti-rabbit IgG (H and L), rabbit anti-goat IgG (H and L) and goat antimouse IgG (H and L) (all from Dianova) incubation, respectively, and final ECL detection. For the detection of V5-tagged sIFN-lR1 and IL-22BP, we used cell lysates (generated as described in Wolk et al. 50 ) and culture supernatants, native or treated with PNGase F (New England Biolabs) to remove N-linked carbohydrates, for immunoblotting (30 mg total protein containing cell lysate and 20 ml culture supernatant per lane for untreated samples; 40 mg total protein containing cell lysate and 15 ml culture supernatant per lane for deglycosylated 
Flow cytometric analysis
For the detection of intracellular phospho-STAT1 and phospho-STAT3 in PBMCs, we fixed cells for 10 min (BD Cytofix; BD Biosciences), centrifugated at 300 g for 5 min and then permeabilized for 30 min on ice (BD Perm Buffer III, BD Biosciences), followed by two washing steps (phosphate-buffered saline with 2% fetal bovine serum and 2 mM NaN 3 ) and subsequent incubation with R-phycoerythrin (PE)-labeled phospho-STAT1 (clone 4a) and phospho-STAT3 (clone 4) for 30 min in the dark at room temperature. In all analyses of PBMCs, cells were stained in parallel with the following mAbs to allow electronic gating and separate evaluation of subpopulations: fluorescein isothiocyanate-labeled HLA-DR, DQ, DP (clone Tü 39), allophycocyanin-labeled CD3 (clone SK7; BD Biosciences), PE-cyanin 5-labeled CD14 (clone RMO52), fluorescein isothiocyanate-labeled CD16 (clone 3G8), CD56 (clone NCAM16.2) and CD57 (clone NC1) (Beckmann Coulter, Krefeld, Germany).
Cell-surface expression of MHC I was detected using PE-labeled anti-HLA-A, B, C mAb (clone G46-2.6) and PE-labeled IgG1/k isotype mAb (clone MOPC-21) (BD Biosciences). Specific expression was calculated as the difference between the mean fluorescence intensity (MFI; geomean) obtained with the specific and isotype mAb. All analyses were performed by means of a FACSCalibur instrument and CellQuest software (BD Bioscience).
qPCR Panels of mostly pooled total RNA from human tissues were obtained from Clontech Laboratories (Heidelberg, Germany). The number of donors that each specific RNA was derived from was as follows: adrenal gland, 6; bone marrow, 69; brain, 2; fetal brain, 24; cerebellum, 1; colon, 2; heart, 1; kidney, 6; liver, 1; fetal liver, 63; lungs, 2; mammary gland, 8; pancreas, 9; placenta, 7; prostate, 19; salivary gland, 43; skeletal muscle, 12; skin, 6; small intestine, 2; spinal cord, 13; spleen, 6; stomach, 2; testis, 45; thymus, 12; thyroid gland, 53; trachea, 84; uterus, 3. Isolation of total RNA from isolated and/or cultured cells was performed using the Invisorb RNA kit II (Invitek, Berlin, Germany). Messenger RNA was reversetranscribed and quantitative PCR analysis was performed in triplicate assays using the ABI Prism 7700 Sequence Detection System (Applied Biosystems) as described previously. 51, 52 For the detection of total IFN-lR1 and single splice variants, systems purchased from Applied Biosystems, together with the matching system for the housekeeping gene hypoxanthine phosphoribosyl-transferase 1 (HPRT), were used. The analysis of HPRT was included to normalize IFN-lR1 expression, which was carried out by calculating IFNlR1 expression as the value 2 to the power of the difference between the threshold cycles for amplification of HPRT and IFN-lR1.
Conventional PCR, gel electrophoresis and sequencing
For investigating the mRNA expression of IFN-lR1 variants, cDNA was synthesized as described above and PCR was performed. First amplification was designed to cover sequences spanning exons V-VI, whereby the following primers and conditions were used: 5 0 -CAGCCAGTCCAGATCACTCTCC-3 0 and 5 0 -TCCTCAATTTCTGATTCCCTCG-3 0 (Metabion, Martinsried, Germany); initial denaturation for 3 min at 94 1C, followed by 35 cycles with 30 s at 94 1C, 25 s at 62 1C and 45 s at 72 1C; 1.5 and 1.7 mM MgCl 2 . A second amplification was designed to cover sequences spanning exons II-VII using the following primers and conditions: 5 0 -CAGAATGTGACGCTGCTCTC-3 0 and 5 0 -GGACATT GGGGCATTACATG-3 0 ; initial denaturizing for 3 min at 94 1C, followed by 40 cycles at 94 1C for 30 s, 62 1C for 25 s, 72 1C for 60 s, followed by 3 min final extension at 72 1C, using 1.5 mM MgCl 2 . Amplifications were run in a GeneAmp PCR system 9700 (Applied Biosystems). PCR products were separated on 1% agarose gel in Trisacetate-EDTA buffer, purified from agarose gel pieces using the Easy Pure DNA purification kit (Biozym Diagnostik, Hess. Oldendorf, Germany) and checked directly (first PCR) or after reamplification (second PCR) by sequencing using the ABI Prism BigDye Terminator cycle sequencing kit and the ABI 310 capillary electrophoresis genetic analyzer (both from Applied Biosystems).
Binding studies
For the investigation of cytokine-soluble cytokine receptor interactions, we performed kinetic binding experiments using surface plasmon resonance technology as described previously. 43 All measurements were performed using a Biacore X instrument, associated Biacore X 2.2 control software, CM5 sensor chips and HBS-EP as running buffer (all from Biacore, Freiburg, Germany). In brief, IFN-l1 was immobilized on the sensor chip (Biacore) surface of the first flow cell, whereas IL-22, immobilized on the second flow cell, served as a control protein. ) were run over the sensor chip surface of both flow cells at 5 ml min À1 for 10 min. The receptor dose-dependent increase in RU as a measure of the density of ship-bound receptor was assessed. To measure the affinity between sIFN-lR1 and IFN-l1, sIFN-lR1-Fc (second flow cell) and dimeric IL-22BP-Fc (first (reference) flow cell) (both from R&D Systems) were coated on the sensor chip surface by the standard amine coupling chemistry procedure (Biacore). The achieved ligand density after immobilization corresponded to 3050 RU for sIFN-lR1-Fc and 3300 RU for sIL-22BP-Fc. After running different concentrations of IFN-l1 (100, 200, 400, 800, 1200, 1600, 2000 and 2400 ng ml À1 ) at 50 ml min À1 for 2 min over the sensor chip surface, steady-state affinity was calculated with BIAevaluation software (Biacore, Freiburg, Germany) by performing global fitting. All cytokines (carrier free) were purchased from R&D Systems. 
Statistical analyses
Differences between experimental treatment groups obtained with a minimum of five experiments were tested by the Wilcoxon matched-pairs signed-rank test (two-tailed) using SPSS 14.0 software (SPSS Inc., Chicago, IL, USA). An error probability of Po0.05 was considered significant.
